Glenmark Pharmaceuticals trades higher on the bourses

22 Sep 2017 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 637.00, up by 8.25 points or 1.31% from its previous closing of Rs. 628.75 on the BSE.

The scrip opened at Rs. 630.00 and has touched a high and low of Rs. 641.25 and Rs. 629.85 respectively. So far 69439 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 567.95 on 12-Sep-2017.

Last one week high and low of the scrip stood at Rs. 641.25 and Rs. 596.05 respectively. The current market cap of the company is Rs. 17944.32 crore.

The promoters holding in the company stood at 46.53%, while institutions and non-institutions held 38.89% and 14.58% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg, of Pfizer, Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market achieved annual sales of approximately $112.7 million.

Glenmark’s current portfolio consists of 125 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

1961.15 8.25 (0.42%)
11-Dec-2025 12:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.55
Dr. Reddys Lab 1271.00
Cipla 1507.40
Zydus Lifesciences 925.00
Lupin 2078.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×